Immuno-Oncology Therapies Are Being Studied in Multiple Cancer Types
There is a significant amount of research underway to study different approaches in Immuno-Oncology across various cancer types. Bristol-Myers Squibb is committed to providing you with relevant information as it becomes available.
Areas of Research
Colorectal cancer is a type of cancer that starts in either the colon or the rectum. It is a common type of cancer, as the lifetime risk of developing this type of cancer is about 1 in 20. Bristol-Myers Squibb is researching new Immuno-Oncology approaches to help the body fight colorectal cancer cells.
Lung cancer is a type of cancer that forms in the tissues of the lung, usually in the air passages. It is the leading cause of all cancer-related deaths, and every year more people die of lung cancer than of colon, breast, and prostate cancers combined. Bristol-Myers Squibb is currently studying how Immuno-Oncology may affect lung cancer.
Melanoma is the deadliest form of skin cancer. Melanoma is difficult to treat, so there is a need for new treatment options. Bristol-Myers Squibb is committed to its Immuno-Oncology research in patients with melanoma that has spread or cannot be removed by surgery.
Multiple myeloma, the second most common blood cancer in the United States, affects plasma cells in the bone marrow. Some plasma cells may become cancerous and can crowd out healthy blood cells. The cancerous plasma cells, also known as myeloma cells, develop into tumors within bones and produce an abnormal protein known as M protein. This can build up in blood and urine, and potentially cause kidney damage.
Bristol-Myers Squibb is currently researching Immuno-Oncology treatments in these cancer types:
- Cervical Cancer
- Gastric Cancer
- Head and Neck Cancer
- Kidney Cancer
- Liver Cancer
- Lung Cancer
- Multiple Myeloma
- Prostate Cancer